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Abstract: Serum and plasma are commonly used in metabolomic-epidemiology studies.
Their metabolome is susceptible to differences in pre-analytical conditions and the impact of this is
unclear. Participant-matched EDTA-plasma and serum samples were collected from 37 non-fasting
volunteers and profiled using a targeted nuclear magnetic resonance (NMR) metabolomics platform
(n = 151 traits). Correlations and differences in mean of metabolite concentrations were compared
between reference (pre-storage: 4 ◦C, 1.5 h; post-storage: no buffer addition delay or NMR analysis
delay) and four pre-storage blood processing conditions, where samples were incubated at (i) 4 ◦C,
24 h; (ii) 4 ◦C, 48 h; (iii) 21 ◦C, 24 h; and (iv) 21 ◦C, 48 h, before centrifugation; and two post-storage
sample processing conditions in which samples thawed overnight (i) then left for 24 h before addition
of sodium buffer followed by immediate NMR analysis; and (ii) addition of sodium buffer, then
left for 24 h before NMR profiling. We used multilevel linear regression models and Spearman’s
rank correlation coefficients to analyse the data. Most metabolic traits had high rank correlation
and minimal differences in mean concentrations between samples subjected to reference and the
different conditions tested, that may commonly occur in studies. However, glycolysis metabolites,
histidine, acetate and diacylglycerol concentrations may be compromised and this could bias results
in association/causal analyses.
Keywords: metabolomics; serum; plasma; nuclear magnetic resonance; pre-analytical phase
1. Introduction
The development of high-throughput methods for quantifying multiple ‘omic traits in large-scale
epidemiological studies, using stored biosamples, has the potential to rapidly advance our
understanding of how human physiology and metabolism vary across the lifecourse. Applying these
methods to existing samples from very densely pheno- and genotyped cohorts also has the potential to
enhance our understanding of causal mechanisms for disease. To do this in a scientifically rigorous way,
further information is required regarding the potential impact of differing pre-analytical conditions
(e.g., variations in incubation duration and temperature before centrifugation) of stored samples that
are likely to vary between cohorts and potentially within the same cohort over time. For example,
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since sample collection from longitudinal epidemiological cohorts are collected over many decades,
it may be impossible to ensure that identical protocols are used throughout the lifetime of the study.
In clinical cohorts and in pregnancy/birth cohorts, such as the Avon Longitudinal Study of Parents
and Children [1,2] and Born in Bradford [3] cohorts, some samples (e.g., during antenatal care or for
cord-blood) are obtained during routine clinical practice where health care needs takes precedence
over speedy sample processing and rapid storage. Yet these samples, collected early in life, are often
the most valuable for research related to the long-term effects of childhood exposures. Other cohorts
face different challenges, for example, the Health Survey for England [4] and Understanding Society [5]
collect biological samples in participants’ homes, which is likely to increase pre-analytical variability.
Additionally, we are increasingly interested in cohort collaborations (e.g., University College
London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol [6] consortium, COnsortium
of METabolomics Studies [7], Cohorts for Heart and Aging Research in Genomic Epidemiology [8]
consortium) and broader international comparisons, for example, between determinants of health and
well-being in low-, middle- and high-income countries and how these differ. Consequently, we often
need to combine data from samples collected in very different circumstances. For all these reasons, it is
important to recognise that biosample collection protocols are often a compromise between reducing any
effects of pre-analytical variation with maximising the amount of data that can be obtained from samples,
within the financial and practical restraints of a given collection sweep.
In clinical chemistry, pre-analytics account for 60–80% of laboratory errors [9–12], and current
standard operating procedures for blood handling in metabolomics are generally based on best
practices [13] (not evidence-based) for conventional biochemistry tests [9,14]. While several studies
have explored the impact of pre-analytical conditions on a small number of commonly assessed
biomarkers in epidemiology [13,15–18], metabolomics—the simultaneous quantification of large
numbers of metabolic traits—has particular challenges as different metabolites may have different
susceptibilities to degradation [19–23].
The aim of this study was to determine the differences in metabolite concentrations between
reference and six pre-analytical conditions, which reflect conditions potentially arising during sample
collection and processing in large-scale epidemiological studies. We used both Spearman’s rank
correlation and differences in mean concentrations to address this aim. Rank correlations are useful for
considering any impact of pre-analytical effects on subsequent association or causal effect analyses
using metabolomics data, as bias of these results is likely to be minimal if participants are still
ranked similary with respect to metabolite concentrations. Differences in mean concentrations are
important when describing distributions of a metabolite in a population or comparing differences
between populations.
Throughout this manuscript, we use the term pre-storage instead of (sample) pre-processing
to indicate the phase of the metabolomic workflow that occurs before long-term storage of samples.
This was done to avoid confusion with the term (data) pre-processing which is used, particularly
in untargeted metabolomic studies, to mean the several steps undertaken after metabolomics data
acquisition (e.g., peak alignment, normalization).
2. Results
Characteristics of study participants are shown in Table 1, with metabolic trait distributions in
Table S1, Supplementary Materials. Most participants were female (78%) and 46% were between
21 and 35 years old; 41% had drunk alcohol within the 24 h period prior to blood sampling.
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Table 1. Characteristics of study participants (N = 37) who contributed to at least one pair of
exposure-outcome analysis. Age was collected in categories.
Characteristics n %
Female 29 78
Age
(21–35) 17 46
(36–50) 10 27
(51–65) 10 27
Ever smoked, No 15 41
Time since last alcohol consumption
Never Drinks 2 5
<1 Week 16 43
1–4 Weeks 4 11
24 h before blood collection 15 41
The following main conclusions can be drawn from our analyses of the effect of pre-analytical
conditions on blood metabolic traits:
• 72% and 93% of metabolic traits across pre- and post-storage conditions, respectively,
had Spearman’s correlations, between metabolite concentrations of samples subjected to
reference and variant conditions, above 0.8 (Tables S2–S5, Supplementary Materials; Figures 1–8;
Figures S1–S4, Supplementary Materials). Exceptions are described in the next two bullet points.
• In both biofluids, diacylglycerol and histidine concentrations had, generally, Spearman’s
correlation coefficient of ~0.5 or lower between reference and variant pre- and post-storage
conditions (Figures 1–7; Tables S2–S5, Supplementary Materials).
• Sphingomyelins, conjugated linoleic acid, lactate, glucose (serum), pyruvate (serum), glycerol
(serum), phenylalanine (EDTA-plasma) and acetate had Spearman rank correlations between ~0.7 and
−0.06 between concentration of samples subjected to variant pre-storage conditions and reference.
• Glycolysis-related metabolites (glucose, lactate, pyruvate) and amino acids showed marked
differences in mean concentration between reference and pre-storage conditions and post-storage
conditions (amino acids only) (Figures S5–S7, Supplementary Materials; Tables S6–S9,
Supplementary Materials).
• Branched and aromatic amino acids had smaller changes in mean differences from the reference
and variant pre-storage conditions in EDTA-plasma than in serum (Figure S5, Supplementary
Materials; Tables S6 and S7, Supplementary Materials).
• For pyruvate, pre-storage delay and temperature appeared to interact, with mean levels slightly
decreasing/stable from reference levels per 24 h at 4 ◦C and increasing per 24 h at 21 ◦C (Figure S5,
Supplementary Materials; Table S6, Supplementary Materials).
• As an illustration of the magnitude of effects in serum, mean levels of glucose decreased by
0.91 mmol/L (95% CI: 0.87 to 0.95) and 1.9 mmol/L (95% CI: 1.7 to 2.1) for each 24 h delay,
compared with the reference sample, at 4 ◦C and 21 ◦C, respectively. Pyruvate levels decreased
by 0.013 mmol/L per 24 h (95% CI: 0.008 to 0.018) at 4 ◦C but increased by 0.73 mmol/L per 24 h
(95% CI: 0.64, 0.82) at 21 ◦C.
• Post-storage conditions affected histidine, phenylalanine and low-density lipoprotein (LDL)
particle size, with differences in mean levels of up to 1.4 SD from reference (Figure S6,
Supplementary Materials; Tables S8 and S9, Supplementary Materials).
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Figure 1. Serum, pre-storage handling effects: Spearman’s rank correlation coefficients between 
metabolic trait concentration/value in reference samples (4 °C, 1.5 h) and samples incubated at (i) 4 
°C, 24 h; (ii) 4 °C, 48 h; (iii) 21 °C, 24 h; and (iv) 21 °C, 48 h, before centrifugation (correlations for 
lipoprotein trait details are given in Figure S1, Supplementary Materials). Spearman’s rank correlation 
coefficients and 95% confidence intervals (CIs) are listed in Table S2, Supplementary Materials. C, 
cholesterol; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; VLDL, very low-density lipoprotein. 
Figure 1. Serum, pre-storage handling effects: Spearman’s rank correlation coefficients between
metabolic trait concentration/value in reference samples (4 ◦C, 1.5 h) and samples incubated at (i) 4 ◦C,
24 h; (ii) 4 ◦C, 48 h; (iii) 21 ◦C, 24 h; and (iv) 21 ◦C, 48 h, before centrifugation (correlations for lipoprotein
trait details are given in Figure S1, Supplementary Materials). Spearman’s rank correlation coefficients
and 95% confidence intervals (CIs) are listed in Table S2, Supplementary Materials. C, cholesterol; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL,
very low-density lipoprotein.
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Figure 2. Serum, pre-storage handling effects (Figure 1 continued): Spearman’s rank correlation 
coefficients between metabolic trait concentration/value in reference samples (4 °C, 1.5 h) and samples 
incubated at (i) 4 °C, 24 h; (ii) 4 °C, 48 h; (iii) 21 °C, 24 h; and (iv) 21 °C, 48 h, before centrifugation 
(correlations for lipoprotein trait details are given in Figure S1, Supplementary Materials). 
Spearman’s rank correlation coefficients and 95% confidence intervals (CIs) are listed in Table S2, 
Supplementary Materials. MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. 
Figure 2. Serum, pre-storage handli g effects (Fig re 1 co ti e ): S ear an’s rank correlation
coefficients bet ee etabolic trait concentration/value in reference samples (4 ◦C, 1.5 h) and
samples incubated at (i) 4 ◦C, 24 h; (ii) 4 ◦C, 48 h; (iii) 21 ◦C, 24 h; and (iv) 21 ◦C, 48 h, bef re
centrifugation (c rrelations for lipoprotein trait details are given in Figure S1, Supplementary Materials).
Spearman’s rank correlation coefficie ts c fi e ce i ter als (CIs) are listed in Table S2,
Sup lementary Materials. MUFA, monounsaturated fatty acids; , poly s t r t f tt ci s.
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Figure 3. EDTA-plasma, pre-storage handling effects: Spearman’s rank correlation coefficients 
between metabolic trait concentration/value in reference samples (4 °C, 1.5 h) and samples incubated 
at (i) 4 °C, 24 h; (ii) 4 °C, 48 h; (iii) 21 °C, 24 h; and (iv) 21 °C, 48h, before centrifugation (correlations 
for lipoprotein trait details are given in Figure S2, Supplementary Materials). Spearman’s rank 
correlation coefficients and 95% confidence intervals (CIs) are listed in Table S3, Supplementary 
Materials. C, cholesterol; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, 
high-density lipoprotein; VLDL, very low-density lipoprotein. 
Figure 3. EDTA-plasma, pre-storage handling effects: Spearman’s ra k correlati n coefficients between
metabolic trait concentra ion/value n reference samples (4 ◦C, 1.5 h) and samples incubated at (i) 4 ◦C,
24 h; (ii) 4 ◦C, 8 h; ( ii) 21 ◦C, 24 h; and (iv) 1 ◦C, 48h, before centrifugation (correlations for lipoprotein
trait details ar given in Figure S2, Supplementary Materials). Sp arman’s rank correlation coefficients
and 95% c fidence intervals (CIs) are list d in Table S3, Supplementary Materials. C, cholesterol; IDL,
intermediate-density lip protein; LDL, low-density lipoprotein; HDL, high VLDL,
very low-density li oprotein.
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Figure 4. EDTA-plasma, pre-storage handling effects (Figure 3 continued): Spearman’s rank 
correlation coefficients between metabolic trait concentration/value in reference samples (4 °C, 1.5h) 
and samples incubated at (i) 4 °C, 24 h; (ii) 4 °C, 48 h; (iii) 21 °C, 24 h; and (iv) 21 °C, 48 h, before 
centrifugation (correlations for lipoprotein trait details are given in Figure S2, Supplementary 
Materials). Spearman’s rank correlation coefficients and 95% confidence intervals (CIs) are listed in 
Table S3, Supplementary Materials. MUFA, monounsaturated fatty acids; PUFA, polyunsaturated 
fatty acids. 
Figure 4. EDTA-plasma, pre-storage handling effects (Figure 3 continued): Spearman’s rank correlation
coefficients between metabolic trait concentration/value in reference samples (4 ◦C, 1.5h) and
samples incubated at (i) 4 ◦C, 24 h; (ii) 4 ◦C, 48 h; (iii) 21 ◦C, 24 h; and (iv) 21 ◦C, 48 h, before
centrifugation (correlations for lipoprotein trait details are given in Figure S2, Supplementary Materials).
Spearman’s rank correlation coefficients and 95% confidence intervals (CIs) are listed in Table S3,
Supplementary Materials. MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
Metabolites 2019, 9, 64 8 of 21
Metabolites 2018, 8, x FOR PEER REVIEW  8 of 21 
 
 
 
Figure 5. Serum, post-storage handling effects: Spearman’s rank correlation coefficients between 
metabolic trait concentration/value in reference samples (no buffer addition or nuclear magnetic 
resonance (NMR) analysis delays) and samples subjected to two variant post-storage conditions in 
which samples thawed overnight and afterwards (i) were left for 24 h before addition of sodium buffer 
followed by immediate NMR analysis (buffer delay); and (ii) addition of sodium buffer, then left for 
24 h before profiling (NMR delay) (correlations for lipoprotein trait details are given in Figure S3, 
Supplementary Materials). Spearman’s rank correlation coefficients and 95% confidence intervals 
(CIs) are listed in Table S4, Supplementary Materials. C, cholesterol; IDL, intermediate-density 
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very low-density 
lipoprotein. 
Figure 5. Serum, post-storage handling effects: Spearman’s rank correlation coefficients between
metabolic trait concentration/value in reference samples (no buffer addition or nuclear magnetic
resonance (NMR) analysis delays) and samples subjected to two variant post-storage conditions in
which samples thawed overnight and afterwards (i) were left for 24 h before addition of sodium buffer
followed by immediate NMR analysis (buffer delay); and (ii) addition of sodium buffer, then left for
24 h before profiling (NMR delay) (correlations for lipoprotein trait details are given in Figure S3,
Supplementary Materials). Spearman’s rank correlation coefficients and 95% confidence intervals (CIs)
are listed in Table S4, Supplementary Materials. C, cholesterol; IDL, intermediate-density lipoprotein;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein.
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Figure 6. Serum, post-storage handling effects (Figure 5 continued): Spearman’s rank correlation 
coefficients between metabolic trait concentration/value in reference samples (no sample preparation 
or nuclear magnetic resonance (NMR) analysis delays) and samples subjected to two variant post-
storage conditions in which samples thawed overnight and afterwards (i) were left for 24 h before 
addition of sodium buffer followed by immediate NMR analysis (buffer delay); and (ii) addition of 
sodium buffer, then left for 24 h before profiling (NMR delay) (correlations for lipoprotein trait details 
are given in Figure S3, Supplementary Materials). Spearman’s rank correlation coefficients and 95% 
confidence intervals (CIs) are listed in Table S4, Supplementary Materials. MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids. 
Figure 6. Serum, post-storage handling effects (Figure 5 continued): Spearman’s rank correlation
coefficients between metabolic trait concentration/value in reference samples (no sample preparation or
nuclear magnetic resonance (NMR) analysis delays) and samples subjected to two variant post-storage
conditions in which samples thawed overnight and afterwards (i) were left for 24 h before addition of
sodium buffer followed by immediate NMR analysis (buffer delay); and (ii) addition of sodium buffer,
then left for 24 h before profiling (NMR delay) (correlations for lipoprotein trait details are given in
Figure S3, Supplementary Materials). Spearman’s rank correlation coefficients and 95% confidence
intervals (CIs) are listed in Table S4, Supplementary Materials. MUFA, monounsaturated fatty acids;
PUFA, polyunsaturated fatty acids.
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Figure 7. EDTA-plasma, post-storage handling effects: Spearman’s rank correlation coefficients 
between metabolic trait concentration/value in reference samples (no sample preparation or nuclear 
magnetic resonance (NMR) analysis delays) and samples subjected to two variant post-storage 
conditions in which samples thawed overnight and afterwards (i) were left for 24 h before addition 
of sodium buffer followed by immediate NMR analysis (buffer delay); and (ii) addition of sodium 
buffer, then left for 24 h before profiling (NMR delay) (correlations for lipoprotein trait details are 
given in Figure S4, Supplementary Materials). Spearman’s rank correlation coefficients and 95% 
confidence intervals (CIs) are listed in Table S5, Supplementary Materials. C, cholesterol; IDL, 
intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
VLDL, very low-density lipoprotein. 
Figure 7. EDTA-plasma, post-storage handling effects: Spearman’s rank correlation coefficients
between metabolic trait concentration/value in reference samples (no sample preparation or nuclear
magnetic resonance (NMR) analysis delays) and samples subjected to two variant post-storage
conditions in which samples thawed overnight and afterwards (i) were left for 24 h before addition
of sodium buffer followed by immediate NMR analysis (buffer delay); and (ii) addition of sodium
buffer, then left for 24 h before profiling (NMR delay) (correlations for lipoprotein trait details are
given in Figure S4, Supplementary Materials). Spearman’s rank correlation coefficients and 95%
confidence intervals (CIs) are listed in Table S5, Supplementary Materials. C, cholesterol; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL,
very low-density lipoprotein.
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correlation coefficients between metabolic trait concentration/value in reference samples (no sample 
preparation or nuclear magnetic resonance (NMR) analysis delays) and samples subjected to two 
variant post-storage conditions in which samples thawed overnight and afterwards (i) were left for 
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trait details are given in Figure S4, Supplementary Materials). Spearman’s rank correlation coefficients 
and 95% confidence intervals (CIs) are listed in Table S5, Supplementary Materials. MUFA, 
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. 
3. Discussion 
In this experiment, we showed that most metabolites, including lipids, lipoproteins and fatty 
acids, are minimally affected by different sample pre-analytical conditions that were designed to 
reflect plausible variation in large-scale epidemiological studies that collected samples at different 
time points and different populations. We explored the rank correlation and differences in mean 
levels of different pre-analytical conditions for over 151 metabolic traits. The pre-analytical conditions 
that we explored reflect realistic situations in large-scale epidemiological studies. We believe this is 
Figure 8. EDTA-plasma, post-storage handling effects (Figure 7 continued): Spearman’s rank
correlation coefficients between metabolic trait concentration/value in reference samples (no sample
preparation or nuclear magnetic resonance (NMR) analysis delays) and samples subjected to two
variant post-storage conditions in which samples thawed overnight and afterwards (i) were left for 24 h
before addition of sodium buffer followed by immediate NMR analysis (buffer delay); and (ii) addition
of sodium buffer, then left for 24 h before profiling (NMR delay) (correlations for lipoprotein trait details
are given in Figure S4, Supplementary Materials). Spearman’s rank correlation coefficients and 95%
confidence intervals (CIs) are listed in Table S5, Supplementary Materials. MUFA, monounsaturated
fatty acids; PUFA, polyunsaturated fatty acids.
3. Discus ion
In this experiment, we sho e t at t , i li i s, lipoproteins and fa ty
acids, are minimally affected by differe t sa l - l ti l iti s that ere designed to
reflect plausible variation in large-scale e i i l i l st i s t t ll cted sa ples at different
time points and ifferent po ulations. We explored the rank correlation and differences in mean levels
of different pre-analytical conditions for over 151 metabolic traits. The pre-analytical conditions that
we explored reflect realistic situations in large-scale epidemiological studies. We believe this is an
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important contribution to the literature given the increasing use of high-throughput metabolomics in
stored samples from large epidemiological studies.
In this study, 72% and 93% of metabolite traits across pre- and post-storage conditions, respectively,
had Spearman’s correlations, between metabolite concentrations of samples subjected to reference
and variant conditions above 0.8. This suggests that, for most measurements, there is little effect
of different pre-analytical conditions on metabolic concentrations or, where there are effects, these
are similar across paticipants. Most metabolites also had similar mean concentrations between the
reference and different tested pre-analytical conditions (91% and 97%, across pre and post-storage
conditions, respectively, had <0.5 SD), with glycolysis and some amino acids in particular having both,
low rank correlations and high differences in mean concentrations (up to 1.4 SD).
Previous studies examining pre-analytical effects on metabolites have largely explored differences
in mean levels and measured this using clinical chemistry tests [15–18,24], mass spectrometry [14,25–27]
and NMR [19,24,28–32], and with targeted and untargeted platforms. Where it is possible to make
comparisons of these previous studies with our results, these are summarized in Table S10, Supplementary
Materials. Pre-storage delay and incubation temperature of uncentrifuged samples can cause changes
to serum and plasma metabolomes because blood cells and enzymes are still metabolically active
inside the sample tube, resulting in the uptake and release of metabolites. Concordant findings
include the reported stability of triglycerides [16–18], high density lipoprotein-cholesterol (C) [18],
low density lipoprotein-C (4 ◦C) [18], total cholesterol (4 ◦C) [18], apolipoprotein A-I and B [18] and
creatinine [18]. Our observed changes in glucose, pyruvate, lactate and alanine agree with previous
studies [17–19,26,29], and are likely due to blood cell activity, primarily red blood cells (RBC) [23,33].
The absence of RBC in post-storage samples explains why these metabolites are minimally affected
by the tested post-storage conditions [17,20]. Increases in concentrations of most amino acids with
the pre- and post-storage (non-ideal) conditions that we tested here are also consistent with previous
studies [14,29]. One possible reason for this is protein degradation, for example, in the case of
phenylalanine [14,29] accumulation, as it is an uncommon component of proteins and has few
degradation pathways [14]. Glutamine decreased [14,29], converted into glutamate, and high levels
of the latter prevented reliable quantification of pyruvate, since pyruvate only gives one peak in the
1H NMR spectrum, which can be overlapped by glutamate signals. Our results also show that amino
acids in serum are more affected by pre-storage conditions than in EDTA-plasma, possibly due to the
inhibition of metal-dependent proteases by EDTA in the latter, and the activation of a range of proteases
during coagulation, in the former. Histidine and acetate had opposite changes in serum and plasma,
likely due to the influence of the presence/absence of anti-coagulant. Post-storage effects were less
pronounced than pre-storage ones, indicating that most of the sample degradation is related to blood
cell activities [23,34]. Nevertheless, we found changes in histidine and phenylalanine and, although
not directly comparable to the conditions we tested, others [14,19] have reported changes in some
metabolites when delays occur after centrifugation. These are potentially caused by enzymes released
due to cell damage during centrifugation and other proteins [14,19,34]. While our study has explored
the effects on metabolite concentrations using one quantitative NMR platform, we would anticipate
similar results with other metabolomic platforms that measure the same metabolites, as pre-analytic
conditions affect specific metabolites (as described above) rather than being related to the type of
metabolomic platform (only concentration accuracy and precision may differ across platforms).
Potential Bias in Epidemiological Studies of Pre-Analytic Conditions
Rank correlations are useful for considering any impact of pre-analytical effects on subsequent
association or causal effect analyses using metabolomics data (i.e., analytical studies), because the bias
of these results is likely to be minimal if participants are still ranked similarly with respect to metabolite
concentrations. Differences in mean concentrations are important in descriptive studies where the aim
is to describe the distribution of a metabolite in a population or between two populations. For example,
our results suggest that, on average, glucose levels from samples that were left for 24 h at 21 ◦C before
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being processed and then placed in long-term storage would be 1.9 mmol/L lower than the true value.
Therefore, if mean levels of glucose from one study (e.g., from a population of South Asian adults)
where samples had been left for 24 h at 21 ◦C were compared to those from another study (e.g., from
a population of European adults) where samples had been left for no longer than 1.5 h at 4 ◦C (our
reference/ideal conditions), we may incorrectly conclude that mean glucose concentrations are lower
in South Asian compared to European adults or mask higher concentrations in South Asians. In our
study, there was some consistency between the Spearman rank correlation and difference in mean
concentration results. In particular, pre-analytical conditions for glycolysis metabolites and some
amino acids affected both rank correlation and mean differences, and studies with less than ideal
pre-analytical conditions should consider whether any analyses might be biased for these metabolites.
In analytical studies, the extent of any bias or random errors will depend on the particular research
question, the exposure, the outcome and covariable measurements included in the analyses, as well as
sample size. In addition, in association and causal effect analyses, random error and systematic bias
must be considered relative to exposures, outcomes and covariables. For example, if we were interested
in the potential effect of multiple metabolites (exposures) on incident coronary heart disease (CHD)
(outcome), systematic bias would occur if the effect of pre-analytic conditions on metabolites differed
between those who experienced CHD and those who did not (i.e., pre-analytical conditions would
be associated with both, metabolite concentrations and incidence of CHD, therefore pre-analytical
conditions would be a confounder of the association between metabolites and CHD). This could occur
if samples from cases of CHD are handled more often (e.g., have more freeze–thaw cycles) than those
of controls, which may occur in prospective nested case control studies. These cycles may enhance
the impact of pre-analytical effects, particularly for labile metabolites. However, we acknowledge
that we have not assessed that matter here. Random error could also bias results in this example.
Since researchers at the time of collecting and processing serum/plasma are unlikely to know the future
risk of CHD and as sample processing differences are likely to affect all samples similarly within a
study, this may be more likely than systematic bias. In this case, effects of the pre-analytical conditions
are random with respect to CHD and the expectation with random error is that it biases results towards
the null. Let us consider a second example where metabolites are outcomes, for example, if we were
interested in the effect of body mass index (BMI) (exposure) on metabolites (outcomes). As in the first
example, if pre-analytical conditions that result in measurement error in the metabolites are associated
with BMI, there will be systematic bias that, depending on the extent of measurement error and how
strongly, and in which direction, it is related to BMI and confounders, could bias results towards or
away from the null to a large or small extent. If the pre-analytical conditions are not related to BMI,
the expectation would be bias towards the null. A key thing here is whether BMI (or other exposure)
was measured some time before bio-samples were collected (i.e., in prospective studies) or at the same
time (cross-sectional studies). It is not plausible that pre-analytical conditions could (retrospectively)
influence prior measured BMI, and therefore in prospective studies there would be random error with
an expectation of bias towards the null. However, in cross-sectional studies, and in particular if the
exposure of interest was another biomarker measured in the same samples (e.g., if we were looking
at the association of a cytokine with metabolites), then systematic bias is plausible. Regardless of
metabolites being exposure or outcome in the analysis, associations between pre-analytical conditions
and covariables also need to be considered. As with the examples above, random error would be
expected to bias metabolite–covariable associations towards the null and this may result in residual
confounding in the main analyses.
The above discussion and examples refer to single studies with single centres, whereas
metabolomic (and other ‘omic analytical studies) are increasingly multi-studies, something that is
important for replication and increasing sample size. Systematic bias could occur in multi-centre
studies or collaboration pooling results from a number of different studies, if sample handling and
the likelihood of having an outcome (e.g., CHD) or the distribution of an exposure (e.g., BMI) varies
by centre.
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In summary, for most of the metabolites that we assessed there were high rank correlations and
low differences in means between plausible, but less than ideal pre-analytical conditions, compared
with the ideal. However, for the metabolites that show low rank correlation and/or high differences
in mean levels (specifically glycolysis metabolites, histidine, acetate and diacylglycerol), researchers
should consider the extent to which these effects might have biased results towards the null (due to
random error or systematic bias that masks a true effect) or away from the null (due to systematic bias
or the introduction of residual confounding). Ideally, one would want to compare results with other
studies in similar populations that had “ideal” pre-analytic conditions. Such bias and confounding
are likely to be more pronounced in studies with small sample sizes. In large collaborations where
results from several studies are pooled, we would recommend specifically exploring the extent to
which pre-analytic processing might have influenced between-study heterogeneity.
4. Materials and Methods
Samples from 37 healthy volunteers were collected. Exclusion criteria for the study were the
following: clotting/bleeding disorders, anaemia, use of anti-coagulant medication or insulin treatment
and presence of blood borne viruses. Participants provided written informed consent and completed a
questionnaire. Ethical approval for the study was obtained from the South West Frenchay Proportionate
Review Committee, Bristol, UK, reference 14/SW/0087. An overview of the experimental design is
given in Figure 9. Ten venous blood tubes were drawn for each non-fasting participant (5 EDTA-plasma,
5 serum). Further details are provided in Appendix A.
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4.1. Reference Samples
All samples were processed within 1.5 h of blood withdrawal. Once centrifuged, serum and
EDTA-plasma samples were aliquoted into 1.5 mL microtubes (E1415-2240, STARLAB, Milton Keynes,
UK) and immediately frozen and stored at −80 ◦C for one month prior to NMR analysis. Prior to
profiling, frozen samples were thawed in the refrigerator (4 ◦C) overnight, prepared with sodium
phosphate buffer [35–37] and then immediately run through the NMR spectrometer.
4.2. Pre-Storage Handling: Effect of Pre-Centrifugation Delay and Temperature
We compared metabolic trait concentrations, quantified by the NMR platform, between four pre-
and two post-storage conditions and the reference samples. The four pre-storage conditions had the
following combination of incubation temperature/duration before centrifugation (i) 4 ◦C for 24 h;
(ii) 4 ◦C for 48 h; (iii) 21 ◦C for 24 h; and (iv) 21 ◦C for 48 h. These conditions were chosen to reflect
pre-storage variations likely to occur in epidemiological studies. Participant-matched serum and
EDTA-plasma samples were processed according to these four conditions.
4.3. Post-Storage Handling: Effect of Buffer Addition Delay and NMR Profiling Delay
Two variations to the standard Nightingale Health© NMR protocol [35–37] were investigated
to evaluate the impact of sample preparation and instrumental analysis delay. Matched serum and
EDTA-plasma aliquots of each participant previously prepared according to the reference pre-storage
conditions, described above, were subjected to two post-storage conditions. Samples thawed overnight
(4 ◦C) and afterwards were either (i) left for 24 h, at 4 ◦C in the dark, before addition of sodium
phosphate buffer followed by immediate NMR analysis (buffer addition delay); or (ii) addition of
buffer before being left for 24 h, at 4 ◦C in the dark, then NMR profiling (NMR analysis delay).
4.4. Nuclear Magnetic Resonance Metabolomics Platform
A high-throughput NMR metabolomics platform, Nightingale Health©, at the University of
Bristol, was used to quantify up to 151 lipoproteins, lipids and metabolites in serum and plasma.
The platform applies a single experimental setup, providing the simultaneous quantification of routine
lipids, 14 lipoprotein subclasses and lipids transported by these particles, various fatty acids (FA)
and FA traits (e.g., chain length, degree of unsaturation), amino acids, ketone bodies, glycolysis
and gluconeogenesis-related metabolites, fluid balance and one inflammation metabolite. Most of
these are quantified in clinically meaningful concentrations (e.g., mmol/L), and particle size in nm.
Details of this platform and its use in epidemiological studies have been described elsewhere [38–41].
Pyruvate, glycerol and glycine are not quantified in EDTA-plasma samples due to the interfering
resonances of EDTA on their signals.
4.5. Statistical Analysis
We examined both the Spearman’s rank correlation and differences in mean concentrations of
metabolic trait values/concentrations, between reference and six pre-analytical conditions likely to
occur in large-scale epidemiological studies.
All analyses were conducted using participant-matched serum and EDTA-plasma samples.
As bias in subsequent association or causal analyses involving metabolic traits is likely to be minimal
if participants are still ranked similary with respect to metabolite levels (even if there are differences
in mean levels), we considered the rank correlation coefficients between the reference and each
pre-analytical conditions to be our main analyses. Confidence intervals for Spearman’s rank correlation
coefficients were computed by bootstrap with 200 repetitions.
Differences in mean concentrations of metabolite levels between reference and each pre-analytic
condition are particularly important in analyses of distributions within and between populations (i.e.,
descriptive studies). To assess changes in mean concentrations of metabolic traits due to the different
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pre-analytical conditions, we used linear regression models with random intercepts. Such models
account for within individual clustering of observations as each individual participant contributes
with multiple samples for analysis.
All metabolic traits were scaled to standard deviation (SD) units (by subtracting the mean and
dividing by the standard deviation); this was done separately for EDTA-plasma and serum, and pre-
and post-storage conditions. Standardization allows the comparison of metabolic traits with different
units and/or different concentration ranges. Results in measured concentration units (e.g., mmol/L)
are provided in the Supplementary Materials. Full specification of the models can be found in
Appendix A. First, we evaluated the impact of pre-storage duration, before centrifugation, by keeping
temperature constant (at 4 ◦C and 21 ◦C). Incubation duration was entered as a continuous term
(levels: 0 = reference, 1 = 24 h, 2 = 48 h) in the model with betas representing the standardized
mean difference in metabolite concentration per 24 h increment in incubation time at 4 ◦C and 21 ◦C,
respectively. Next, we investigated the impact of post-storage conditions to estimate the standardized
mean difference in metabolite concentration comparing delays in buffer addition and NMR profiling
to the reference (levels: 0 = reference, 1 = buffer addition delay or NMR profiling delay).
Metabolic traits are highly correlated [38]. Nine principal components, in this study, explain
at least 95% of the variance of serum and EDTA-plasma metabolome (see Text S1, Supplementary
Materials), and this number is used to correct conventional p-value thresholds for nominal significance
using the Bonferroni method (alpha = 0.05/9 = 0.006) [41,42]. Here, we focused on effect size and
precision [43,44]. The rationale for defining the number of independent tests via principal component
analysis (PCA) has been discussed previously [25,29,30], and more information is available in Text S1,
Supplementary Materials.
In addition, to better appreciate the effects of pre-storage temperature and duration of incubation
on the overall metabolic profile [45], we also used PCA [46]. In PCA scores plots, the metabolic profile
of each sample is shown as a single data point, therefore each participant is represented by five data
points corresponding to each pre-storage condition. Samples (data points) close to one another have
similar metabolic composition in comparison to samples further apart [47]. Therefore, if pre-storage
conditions do not impact metabolic profiles, samples will not cluster by pre-storage conditions.
Statistical analyses were conducted using R version 3.0.1 (R Foundation for Statistical Computing,
Vienna, Austria).
5. Conclusions
Most serum and EDTA-plasma metabolic traits, quantified by Nightingale Health© NMR platform
(87% of measured traits are lipid-related), are minimally affected by the pre- and post-storage conditions
tested, with the exception of glycolysis metabolites, histidine, acetate and diacylglycerol. Potential bias,
and its magnitude and direction, of association and causal effect estimates as a result of the impact of
pre-analytical conditions, on some metabolites, will depend on the specific research questions being
addressed. This should be considered for analyses with glycolsis metabolites, histadine, acetate and
diaglycerol in particular. Furthermore, in large collaborations where data are pooled from different
studies, the possible impact of pre-analytical conditions on between-study heterogeneity should
be explored.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/9/4/64/s1,
Text S1: Multiple testing correction: Principal component analysis (PCA) based Bonferroni correction, Figure S1:
Serum, pre-storage handling effects (Spearman’s rank correlation), Figure S2: EDTA-plasma, pre-storage
handling effects (Spearman’s rank correlation), Figure S3: Serum, post-storage handling effects (Spearman’s rank
correlation), Figure S4: EDTA-plasma, post-storage handling effects (Spearman’s rank correlation), Figure S5:
Pre-storage handling effects: standardized mean differences in metabolic trait concentration, in serum and
EDTA-plasma, per 24 h increment in incubation duration at 4 ◦C and 21 ◦C, Figure S6: Post-storage handling
effects: standardized mean differences in metabolic trait concentration, in serum and EDTA-plasma, comparing
delays in sample preparation (i.e., 24 h delay in buffer addition) and NMR profiling (i.e., 24 h delay in NMR
analysis) to the reference (no delays), for serum and plasma samples, Figure S7: Principal component analysis
(PCA) on serum non-lipid-related metabolic traits subjected to five different pre-storage conditions, Table S1:
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Characteristics of metabolic traits: metabolic trait concentration (or value) in serum and EDTA-plasma samples,
subjected to the reference pre- and post-storage conditions, from individuals who contributed to at least one
pair of exposure–outcome analysis (N = 37), Table S2: Spearman’s correlation: serum, pre-storage handling
effects. Spearman’s rank correlation coefficients between metabolic trait concentrations (or values) in reference
samples (condition: 4 ◦C, 1.5 h) and samples incubated at (i) 4 ◦C, 24 h; (ii) 4 ◦C, 48 h; (iii) 21 ◦C, 24 h; and
(iv) 21 ◦C, 48 h, before centrifugation, Table S3: Spearman’s correlation: EDTA-plasma, pre-storage handling
effects. Spearman’s rank correlation coefficients between metabolic concentrations (or values) in reference samples
(conditions: 4 ◦C, 1.5 h) and samples incubated at (i) 4 ◦C, 24 h; (ii) 4 ◦C, 48 h; (iii) 21 ◦C, 24 h; and (iv) 21 ◦C,
48 h, before centrifugation, Table S4: Spearman’s correlation: serum, post-storage handling effects. Spearman’s
rank correlation coefficients between metabolic concentrations (or values) in reference conditions samples (i.e.,
no buffer addition delay or NMR analysis delay) and samples (i) left for 24 h before addition of sodium buffer
followed by immediate NMR analysis (i.e., buffer delay); and (ii) addition of sodium buffer, then left for 24 h before
NMR analysis (i.e., NMR delay), Table S5: Spearman’s correlation: EDTA-plasma, post-storage handling effects.
Spearman’s rank correlation coefficients between metabolic concentrations (or values) in reference conditions
samples (i.e., no buffer addition delay or NMR analysis delay) and samples (i) left for 24 h before addition
of sodium buffer followed by immediate NMR analysis (i.e., buffer delay); and (ii) addition of sodium buffer,
then left for 24 h before NMR analysis (i.e., NMR delay), Table S6: Serum, pre-storage handling effects: mean
differences in metabolite concentrations (or trait value) per 24 h increment in incubation duration at 4 ◦C and
21 ◦C, for serum samples, Table S7: EDTA-plasma, pre-storage handling effects: mean differences in metabolite
concentrations (or trait value) per 24 h increment in incubation duration at 4 ◦C and 21 ◦C, for EDTA-plasma
samples, Table S8: Serum, post-storage handling effects: mean differences in metabolite concentrations (or
trait value) comparing delays in buffer addition (i.e., buffer delay) and NMR profiling (i.e., NMR delay) to the
reference (no delays), for serum samples, Table S9: EDTA-plasma, post-storage handling effects: mean differences
in metabolite concentrations (or trait value) comparing delays in buffer addition (i.e., buffer delay) and NMR
profiling (i.e., NMR delay) to the reference (no delays), for EDTA-plasma samples, Table S10: Literature table:
summary of previous studies assessing the effects of pre- and post-storage handling conditions on serum or
plasma metabolic traits also measured by Nightingale Health© NMR platform.
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Appendix A
Appendix A.1. Supplementary Methods
Order of blood collection was (i) 5 × 5 mL serum SSTII (NHS supply chain KFK114), (ii) 1 ×
6 mL K2 EDTA (NHS supply chain KFK286) and (iii) 4 × 4 mL K3 EDTA (NHS supply chain KFK042).
Immediately after blood withdrawal, each of the serum and EDTA-plasma tubes was inverted 6 and
8–10 times, respectively. Serum and EDTA-plasma samples were stored on ice while transported to
the laboratory.
Appendix A.2. Reference Samples
Serum tubes were placed upright in a tube rack in the refrigerator (4 ◦C) for 45 min to allow blood
clotting, then centrifuged at speed 1500× g for 10 min at 18–25 ◦C (3K15, Sigma Laborzentrifugen,
Osterode am Harz, Germany). EDTA-plasma tubes were centrifuged as soon as possible after blood
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withdrawal at 2260× g for 10 min at 4–5 ◦C (Heraeus Megafuge 16R, Thermo Scientific, city, state
abbreviation, county).
Appendix A.3. Pre-storage Handling: Effect of Pre-Storage Delay and Temperature
Serum and plasma tubes were covered with tin foil and kept upright in a tube rack, and afterwards
stored on a roller mixer in the dark (Bibby Scientific©,Stone, UK) at 4 ◦C or 21 ◦C, for 24 h or 48 h prior
to centrifugation. Centrifugation was performed as per the reference protocol; subsequently, samples
were aliquoted and immediately frozen and stored at −80 ◦C for one month until nuclear magnetic
resonance (NMR) analysis.
Appendix A.4. Nuclear Magnetic Resonance (NMR) Metabolomics Platform
Up to 230 quantified metabolomic measures were obtained per sample of serum or EDTA-plasma,
using a 1D proton (1H) NMR spectroscopy-based platform described previously [35–37]. Briefly, 260
µL plasma and 260 µL sodium phosphate buffer (75 mM Na2HPO4, 0.08% sodium 3-(trimethylsilyl)
propionate-2,2,3,3-d4, 0.04% sodium azide in 80%/20% H2O/D2O, pH 7.4) were mixed and transferred to
NMR tubes using an 8-channel, Varispan Janus liquid handling robot (PerkinElmer, Waltham, MA, USA).
NMR spectra were acquired using a Bruker Avance III HD 500MHz spectrometer (Billerica, MA, USA)
with a room temperature 5 mm, inverse triple resonance TXI probe and a Bruker Avance III HD 600 MHz
spectrometer (Billerica, MA, USA) equipped with a nitrogen-cooled triple resonance probe (CryoProbe
Prodigy TCI, Billerica, MA, USA). Both spectrometers were equipped with SampleJet auto-samplers with
cooled (6 ◦C) sample storage. Spectra were acquired using standardized parameters via three NMR
experiments or “molecular windows” to characterize lipoproteins, low molecular weight metabolites and
lipids. Lipid spectra were acquired after a standardised lipid extraction procedure performed on each
sample using a VIAFLO 96 channel electronic pipette (Integra Biosciences, Tardisstrasse, Switzerland).
Data pre-processing and quantification were as previously described [35–37].
Appendix A.5. Statistical Analysis
Specification of random intercept model for analysis of pre-storage and post-storage conditions:
yij = β0 + µ0j + (β1)xij + eij, (A1)
where yij is the standardized or unstandardized (for figures and tables, respectively) metabolite
concentration at each condition (xij) for individual j and β0 representing the average intercept of the
model or the overall mean. Deviations from the average intercept for individual j is represented by
µ0j. The eij term describes the deviation of the ith measurement on the jth individual from the mean
standardized (or mean) metabolite concentration. This is the residual error term. For our analysis, β1 is
the fixed parameter of interest, representing the standardized mean (or mean) difference in metabolite
concentration for a 1-unit increase in xij. For analysis of pre-storage conditions, incubation duration
was entered as continuous term in the model (levels: 0 = 1.5 h [reference], 1 = 24 h, 2 = 48 h) with β1
representing the standardized mean (or mean) difference in metabolite concentration for each 24 h
increment in pre-storage incubation duration. This pre-storage condition model was run separately
for samples incubated at 4 ◦C and 21 ◦C and for serum and EDTA-plasma samples. For analysis
of post-storage conditions, β1 is estimated for each level of post-storage condition, representing
the standardized mean (or mean) difference in metabolite concentration comparing delays in (a)
post-storage buffer addition and (b) NMR profiling, to the reference (levels: 0 = no delays in buffer
addition or NMR profiling [reference], 1 = buffer addition delay or NMR profiling delay).
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